Piramal Pharma Solutions Achieves Regulatory Compliance
Piramal Pharma Solutions is at the forefront of addressing regulatory requirements regarding nitrosamine impurities. With a robust plan in place, the company has committed to ensuring the safety of its pharmaceutical products by following comprehensive risk assessments and implement control strategies.
Investment in Safety and Compliance
The organization's proactive stance includes significant investments in site improvements and capability enhancements. This dedication enables Piramal Pharma Solutions to continuously align with international regulatory standards concerning nitrosamines.
Core Team for Compliance
A pivotal aspect of the compliance journey was the establishment of a cross-functional core team that includes experts in Regulatory Affairs, Central Quality, R&D, and Manufacturing. Working together, these experts have provided insights that shaped the company's compliance strategies according to evolving guidelines.
Multi-Step Action Plan
Piramal Pharma's action plan has been multi-faceted. It started with the creation of a specialized Position Paper to guide operations and clarify the roles and responsibilities relating to nitrosamine compliance. This document serves as a central resource that aligns the organization’s efforts with the latest regulatory expectations.
Ensuring Patient Safety
A top priority for Piramal has been the risk assessment of all drug substances and products for potential nitrosamine levels. Each product has undergone thorough confirmatory testing, and stringent control measures have been put into place to mitigate any associated risks. Currently, all commercial products meet the global regulatory standards, while select customer products are awaiting final approval; new productions are only initiated after confirmation of compliance.
Enhanced Testing Capabilities
The company has focused on developing in-house testing capabilities alongside qualifying external laboratories to bolster additional testing requirements. Investments in advanced equipment at key sites have further accelerated their compliance processes and addressed the industry's challenges regarding impurity standards.
Commitment to Excellence
Piramal Pharma Solutions emphasizes that patient well-being is paramount. According to Rashida Najmi, the Chief Quality Officer, the company's achievement in regulatory compliance for nitrosamine impurities reflects its dedication to operational excellence and patient safety. As global guidelines continue to evolve, the company remains committed to supporting its partners through continuous communication and improvement.
About Piramal Pharma Solutions
Piramal Pharma Solutions is a leading Contract Development and Manufacturing Organization (CDMO), offering comprehensive solutions spanning the entire drug lifecycle. With a strong global network, it provides diverse services, including drug discovery, process development, clinical trial supplies, and potent solid oral drug products.
Frequently Asked Questions
What are nitrosamine impurities?
Nitrosamine impurities are unintended carcinogenic byproducts that may occur in certain medications, posing potential health risks.
How is Piramal Pharma Solutions ensuring compliance?
The company has implemented a multi-step action plan, conducted risk assessments, and established new testing capabilities to adhere to regulatory standards.
Who leads the quality compliance efforts at Piramal?
Rashida Najmi, the Chief Quality Officer, leads the initiatives to ensure adherence to nitrosamine regulatory guidelines.
What investments has Piramal Pharma made for compliance?
Piramal Pharma has invested in state-of-the-art equipment and enhanced capabilities for testing and regulatory alignment.
How does Piramal Pharma engage with global partners?
The organization prioritizes transparent communication and continuous improvement in its collaborative efforts with partners to ensure compliance.
